WVE 007
Alternative Names: INHBE targeting siRNA - WaVe life Sciences; WVE-007Latest Information Update: 09 Sep 2024
At a glance
- Originator WaVe life Sciences
- Developer GSK; WaVe life Sciences
- Class Drug conjugates; Hexosamines; Obesity therapies; Small interfering RNA
- Mechanism of Action INHBE protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders; Obesity